<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Enalapril</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00584</strong>&#160; (APRD00510)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Enalapril is a prodrug that belongs to the angiotensin-converting enzyme (<span class="caps">ACE</span>) inhibitor class of medications. It is rapidly metabolized in the liver to enalaprilat following oral administration. Enalaprilat is a potent, competitive inhibitor of <span class="caps">ACE</span>, the enzyme responsible for the conversion of angiotensin I (<span class="caps">ATI</span>) to angiotensin II (<span class="caps">ATII</span>). <span class="caps">ATII</span> regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (<span class="caps">RAAS</span>). Enalapril may be used to treat essential or renovascular hypertension and symptomatic congestive heart failure.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00584/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00584/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00584.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00584.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00584.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00584.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00584.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00584">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Enalapril</td><td>French/German/Spanish</td><td>INN</td></tr><tr><td>Enalaprilum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Enalapril Maleate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT001036/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT001036/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT001036">DBSALT001036</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Acetec</td><td>Alphapharm</td></tr><tr><td>Acetensil</td><td>Gr&#252;nenthal</td></tr><tr><td>Alapren</td><td>Ranbaxy</td></tr><tr><td>Amotac</td><td>Mass Pharma</td></tr><tr><td>Amprace</td><td>Merck Sharp &amp; Dohme</td></tr><tr><td>Dilvas</td><td>Cipla</td></tr><tr><td>Diotensil</td><td>Mintlab</td></tr><tr><td>Drepatil</td><td>Fada</td></tr><tr><td>Enace</td><td>Abbott</td></tr><tr><td>EnaHexal</td><td>Sandoz</td></tr><tr><td>Enal</td><td>East West</td></tr><tr><td>Enalapoten</td><td>Del Bel</td></tr><tr><td>Enalaprilat</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Enpril</td><td>Wockhardt</td></tr><tr><td>Feliberal</td><td>Silanes</td></tr><tr><td>Gadopril</td><td>Gador (Argentina)</td></tr><tr><td>Glioten</td><td>Bago</td></tr><tr><td>Kinfil</td><td>Nova Argentia (Argentina)</td></tr><tr><td>Vasotec</td><td>Merck Frosst (Canada)</td></tr><tr><td>Vasotec IV</td><td>Sandoz (Canada)</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Enzide</td><td>Enalapril and Hydrochlorothiazide</td></tr><tr><td>Lexxel</td><td>enalapril maleate + felodipine</td></tr><tr><td>Vaseretic</td><td>enalapril maleate + hydrochlorothiazide</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/angiotensin-converting-enzyme-inhibitors">Angiotensin-Converting Enzyme Inhibitors</a></li>
<li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>75847-73-3</td></tr><tr><th>Weight</th><td>Average: 376.4467<br>Monoisotopic: 376.199822016</td></tr><tr><th>Chemical Formula</th><td>C<sub>20</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>GBXSMTUPTTWBMN-XIRDDKMYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2S)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]pyrrolidine-2-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td>N-acyl-alpha Amino Acids; Alpha Amino Acid Esters; Alpha Amino Acid Amides; Phenylpropylamines; Pyrrolidine Carboxylic Acids; Fatty Acid Esters; Dicarboxylic Acids and Derivatives; Tertiary Carboxylic Acid Amides; Tertiary Amines; Carboxylic Acid Esters; Carboxylic Acids; Dialkylamines; Polyamines; Enolates; Ethers</td></tr><tr><th>Substituents</th><td>n-acyl-alpha amino acid or derivative; alpha-amino acid ester; n-acyl-alpha-amino acid; alpha-amino acid amide; alpha-amino acid or derivative; phenylpropylamine; pyrrolidine carboxylic acid or derivative; pyrrolidine carboxylic acid; fatty acid ester; dicarboxylic acid derivative; benzene; pyrrolidine; tertiary carboxylic acid amide; tertiary amine; carboxamide group; carboxylic acid ester; polyamine; secondary amine; carboxylic acid; ether; enolate; secondary aliphatic amine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of essential or renovascular hypertension and symptomatic congestive heart failure. It may be used alone or in combination with thiazide diuretics.</td></tr><tr><th>Pharmacodynamics</th><td>Enalapril is a prodrug that is rapidly metabolized by liver esterases to enalaprilat following oral administration. Enalapril itself has little pharmacologic activity. Enalaprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of enalaprilat by causing increased vasodilation and decreased blood pressure.</td></tr><tr><th>Mechanism of action</th><td>There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Enalaprilat, the principle active metabolite of enalapril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Enalapril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors. Enalaprilat's affinity for ACE is approximately 200,000 times greater than that of ATI and 300-1000 times greater than that enalapril. </td></tr><tr><th>Absorption</th><td>55-75%, absorption is unaffected by food; enalaprilat (clinically administered IV) is poorly absorbed, 3-12%, due to its high polarity. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>50-60% of enalaprilat is bound to plasma proteins</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>~ 60% of absorbed dose is extensively hydrolyzed to enalaprilat, primarily by liver esterases</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Enalapril</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01269">Enalaprilat</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1429">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Excretion of enalapril is primarily renal.</td></tr><tr><th>Half life</th><td></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Overdosage may result in marked hypotension and stupor. Most common adverse effects include hypotension, headache, dizziness and fatigue. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Enalapril Action Pathway</td><td>Drug action</td></tr><tr><td>Enalapril Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00593?highlight%5Bcompounds%5D%5B%5D=DB00584&amp;highlight%5Bproteins%5D%5B%5D=DB00584">SMP00593</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.7428</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9659</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8956</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7691</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6681</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5136</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8442</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8632</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5696</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9125</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9154</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6825</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9383
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9216
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.8686
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.8269 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9719
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7456
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Apotex inc</li>
<li>Apothecon inc div bristol myers squibb</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Krka dd novo mesto</li>
<li>Lek pharmaceuticals d d</li>
<li>Mylan pharmaceuticals inc</li>
<li>Ranbaxy laboratories ltd</li>
<li>Sandoz inc</li>
<li>Taro pharmaceutical industries ltd</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc</li>
<li>Wockhardt americas inc</li>
<li>Biovail laboratories international srl</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Hikma farmaceutica (portugal) sa</li>
<li>Hospira inc</li>
<li>Teva parenteral medicines inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apacepak.com">Apace Packaging</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li>BTA Pharmaceuticals</li>
<li>California Clinical Pharmacy Inc.</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li><a href="http://www.corepharma.com">Corepharma LLC</a></li>
<li>Coupler Enterprises Inc.</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.emcure.co.in">Emcure Pharmaceuticals Ltd.</a></li>
<li>Eon Labs</li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.hikma.com">Hikma Pharmaceuticals</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li>Ivax Pharmaceuticals</li>
<li><a href="http://www.krka.biz">Krka d.d. Novo Mesto</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.lek.si">Lek Pharmaceuticals Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.merck.com">Merck &amp; Co.</a></li>
<li>Merrell Pharmaceuticals Inc.</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.ohmlabs.com">Ohm Laboratories Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.pharmpakinc.com">Pharmpak Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Intravenous</td><td>1.25 mg/ml</td></tr><tr><td>Tablet</td><td>Oral</td><td>10 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>2.5 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>20 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>5 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00594">Amiloride</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB08822">Azilsartan medoxomil</a></td><td>Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  </td></tr><tr><td><a href="/drugs/DB01395">Drospirenone</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB06196">Icatibant</a></td><td>Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00046">Insulin Lispro</a></td><td>Concomitant therapy with ACE inhibitors may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. </td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>The ACE inhibitor increases serum levels of lithium</td></tr><tr><td><a href="/drugs/DB01345">Potassium</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin, a strong CYP3A4 inducer, may increase the metabolism of enalapril. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of enalapril if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00421">Spironolactone</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00697">Tizanidine</a></td><td>Tizanidine increases the risk of hypotension with the ACE inhibitor</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00384">Triamterene</a></td><td>Increased risk of hyperkalemia</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Enalapril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia. </li>
<li>Herbs that may attenuate the antihypertensive effect of enalapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.  </li>
<li>High salt intake may attenuate the antihypertensive effect of enalapril.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>